Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mortgage Advice Bureau beats own guidance with H1 results

(Sharecast News) - Mortgage Advice Bureau's share price jumped on Tuesday after the UK mortgage network and broker delivered first-half results slightly ahead of guidance and gave an upbeat assessment of the industry. The company reported revenues of £148.2m for the six months to 30 June, up 19.6% over last year and marginally above the £147m guided to in a trading update in July.

Adjusted pre-tax profit improved 18.4% to £14.5m, ahead of the £14m guidance.

Results were supporting by a jump in overall new mortgage lending, with the total industry lending £134bn during the period, up 22% on last year, as the recovery continued to accelerate following a 7% increase in lending across 2024 as a whole.

Momentum has also been helped by many house purchases being fast-tracked to the first quarter ahead of the planned reduction in Stamp Duty relief from April onwards.

MAB's total mortgage completions rose by 17% to £14.2bn in the first half, which it said "significantly outperform[ed] the market".

Looking ahead, the company said that housing demand is expected to strengthen through the second half of 2025 and into 2026, "supported by greater lender stress-test flexibility, improved affordability, and sharp increases in product maturities".

MAB said it was trading in line with expectations for the second half.

"The impact of past economic shocks is now receding for both borrowers and lenders, creating a more stable operating environment. While uncertainty ahead of the November 2025 Budget may weigh on market sentiment in the near term, certain housing policy measures under discussion could provide opportunities for both MAB and our customers."

The stock was up 8.5% at 738p by 1022 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.